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Introduction: inflammation and proteolysis are important processes in the development of abdominal aortic aneurysms
(AAAs). Prostaglandin E2 (PGE2) (a product of cyclo-oxygenase 2), other inflammatory mediators and proteolytic
enzymes are produced in high quantities in the aneurysm wall. We developed an explant culture system for AAA tissue
to assess the effects of potential drug therapies.
Methods: full thickness biopsies of human AAA were established in culture in the presence or absence of indomethacin
(a cyclo-oxygenase-2 inhibitor). The conditioned medium was collected at 48 h intervals and analysed for products of
collagen breakdown, matrix metalloproteinases, PGE2 and inflammatory cytokines. Explant viability was assessed by
histology, glucose consumption, lactate dehydrogenase release and demonstration of protein synthesis in the tissue.
Results: nuclear morphology was maintained for 4 or more days and this, together with biochemical assays, indicated
that AAA explants were viable in short-term culture. Indomethacin (10 lM) markedly reduced AAA explant production
of prostaglandin E2 from 320 ng/ml to 3.3 ng/ml (p=0.028, n=6). Indomethacin also reduced the release of interleukin-
1b (IL-1b) (from 166 pg/ml to 9.8 pg/ml, p=0.04, n=5) and interleukin-6 (IL-6) (from 119 ng/ml to 57 ng/ml, p=
0.028, n=6), but had no effect on monocyte chemotactic protein 1 or matrix metalloproteinase-9 secretion.
Conclusions: short-term explants of AAA are a novel method to assess the effects of drugs on aneurysm tissue.
Indomethacin reduces the production of PGE2, IL-1b and IL-6, suggesting that cyclo-oxygenase-2 inhibitors may control
the inflammation in the aneurysm wall and potentially limit AAA growth.
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Introduction hypertension has also been implicated.9 Currently,
there is no evidence in the form of controlled trials
that modification of risk factors such as smoking andAbdominal aortic aneurysms (AAAs) are increasingly
hypertension slows AAA expansion.common, affecting 1 in 20 of the male population over
Increasing aortic dilatation results from haemo-the age of 65.1 The underlying cause of aneurysmal
dynamic load on a weakened vessel wall. The vasculardilatation of the aorta is unknown. The strong familial
remodelling comprises a complex series of cell–cell andtendency to AAA formation suggests that genetic pre-
cell–matrix interactions in the aortic wall in response todisposition is important,2 but, though a number of
unknown stimuli.10 The prominent histological fea-candidate genes have been identified,3,4 a genetic basis
tures are thinning of the aortic media with loss offor AAA remains unclear.
aortic smooth muscle and degradation of elastin andInterest is mounting in the potential role of infective
collagen. The degradation of elastin and collagen isagents in vascular disease. Prominent amongst these
probably the result of excessive matrix proteolyticis Chlamydia pneumoniae, an intracellular pathogen
activity. Excessive proteolytic destruction of the extra-which is associated with ischaemic heart disease.5 C.
cellular matrix driven by chronic inflammation in thepneumoniae DNA is present in the wall of about half of
outer wall of the aorta is central to aneurysm de-all AAAs, but no causative link has been established.6
velopment.11 The inflammatory cells infiltrating aorticA number of factors affect the rate at which an
aneurysms are principally B lymphocytes and macro-AAA dilates.7 Inherited factors may play a role. Aortic
phages present throughout the adventitia and media.12aneurysms appear to expand faster in smokers8 and
Matrix metalloproteinases-2 and -9, in particular, are
present in high levels in both active and inactive
forms.12 An important source of matrix metallo-* Please address all correspondence to: I. J. Franklin, Department
of Vascular Surgery, Charing Cross Hospital, London W6 8RF, U.K. proteinase (MMP) secretion in the aneurysm wall is
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infiltrating macrophages.13 These cells secrete a range divided into two, and one of each pair incubated in
the presence of 0.1% sodium azide. After four hoursof mediators, in particular prostaglandin E2 (PGE2)
and inflammatory cytokines, which sustain the in- the medium was replaced to remove leucine present
in the explants. Tritiated leucine solution (250 lCi/ml,flammatory process.3,14 Interruption of these in-
flammatory processes provides a potential therapeutic final concentration 200 lM) was then added to the
culture medium for four hours followed by a 40-houravenue to control AAA growth rates.
The aim of this work was to develop a system of chase in leucine-containing medium. After the 48 hours
of culture the explants were washed in phosphate-explant culture using human aneurysm biopsies to
test the effects of potential therapeutic agents on the buffered saline and stored at -70 °C. The soluble
protein was extracted by homogenisation using a Po-proteolytic and inflammatory processes occurring in
the aneurysm wall. The very high secretion of PGE2 lytron in 25 mM Tris/Cl-, pH 7.6, containing 0.2 M
sodium chloride, 1 M urea and 1 mM EDTA (6 ml/gfrom aortic aneurysm tissue, but not normal aorta,
reported previously,14 prompted the first series of ex- tissue). The supernatants were separated by cen-
trifugation (3500 g for 10 minutes) and the pellet dis-periments to investigate the hypothesis that PGE2 was
a pivotal inflammatory mediator in the aneurysm wall. carded. Trichloracetic acid (50%) was added to each
supernatant (1:1 by volume) at room temperature for
15 minutes to precipitate protein. After centrifugation
(10 000 g for 10 minutes) the protein pellet was re-
Methods suspended in tris-buffered saline (TBS) and the wash-
ing/precipitation step repeated twice more to remove
Characterisation of AAA explant cultures free radiolabelled leucine. Finally, the pellets were
resuspended in 0.5 ml TBS and added to 4 ml scintillant
Retrieval of specimens, culture methods, harvesting of con- (Ecoscint) for scintillation counting.
ditioned medium. Biopsies of the anterior wall of AAAs
were obtained from patients undergoing open surgical (ii) Metabolic labelling and immunoprecipitation of
aneurysm repair. Each specimen was placed in sterile monocyte chemotactic protein-1 (MCP-1). Paired ex-
culture medium (Dulbecco’s modified Eagle’s medium plants were cultured in the presence and absence
(DMEM)), supplemented with antibiotics and trans- of azide and metabolically labelled with [3H]leucine
ported to the laboratory. The tissue was processed (5 Tbq/mmol) as described above. Conditioned
within 1 hour under sterile conditions. medium was harvested and cleared by incubation
Specimens were washed free of blood with culture with protein A-sepharose (Sigma) at 4 °C for 2 h. The
medium and divided into approximately equal-sized supernatant was incubated with a neutralising mono-
pieces, typically 0.2 to 0.5 g wet weight. Each was clonal antibody to monocyte chemotactic protein-1
placed in a 30-mm culture dish, luminal surface up- (MCP-1) (R&D Systems, Abingdon, U.K.) overnight at
permost, bathed in culture medium (1 ml medium 4 °C. Protein A-sepharose (50 ll) was added and the
per 0.1 g wet weight of tissue) and incubated under mixture incubated for a further 2 h. The protein A-
standard conditions of 37 °C in 4% carbon dioxide. sepharose was harvested by centrifugation and pro-
The culture medium was replaced every 48 hours, the teins eluted by boiling with 0.1% SDS for 5 min and
collected medium centrifuged (10 000 g for 60 seconds) analysed by SDS/polyacrylamide gel electrophoresis
to remove particulate debris, and frozen in aliquots at under reducing conditions, followed by auto-
-70 °C until analysed. radiography.
Histology. Tissue samples were fixed in formalin and Analysis of conditioned media. Glucose and lactate de-
embedded in paraffin for histological examination hydrogenase (LDH) were measured by enzymatic as-
with haematoxylin and eosin, and elastin Van Gieson says. Hydroxyproline was determined by colorimetric
staining. Samples were studied fresh and after 2, 4 assay (Dr M. Bayliss, personal communication). Stand-
and 6 days in culture. The tissues were assessed for ard solutions of hydroxyproline (0 to 5 lg/ml) were
morphological integrity, nuclear disruption and other prepared fresh for each assay using DMEM culture
evidence of cell death. medium as diluant. Standards and samples (90 ll)
were placed in duplicate into a 96-well microtitre plate.
Chloramine-T (250 mg in 10 ml 60% methoxymethanolProtein synthesis. (i) Total protein. For these ex-
periments the explants were incubated in leucine-free in assay buffer) was added (90 ll per well) and the
plate shaken on a mechanical plate shaker for 20culture. The specimens were retrieved and established
in culture as described above. Each tissue sample was minutes. Perchloric acid (45 ll, 20%) was added to
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Table 1. Assay systems used for analysis of conditioned media from AAA explants.
Substance measured Assay system
PGE2 Biotrak ELISA system, Amersham Life Science
IL-1b Diaclone Research, ELISA
IL-6 Pelikine Compact ELISA kit, CLB
MCP-1 S. Harley, Dept Vascular Surgery, ICSM, Charing Cross Hospital, ELISA
TNF-a Dr M. Feldmann, Kennedy Institute, ELISA
IFN-c Pelikine Compact ELISA kit, CLB
MMP-9 Biotrak ELISA system, Amersham Life Science
each well and the plate shaken for a further 5 minutes. Results
Finally, 45 ll Ehrlich’s reagent (1 g in 10 ml meth-
oxymethanol) was added, the plate shaken for 10 AAA explant culture characterisation
minutes, then heated to 60 °C for 30–45 minutes until
adequate colour developed. The plate was read at Histological appearances of the explants were well
maintained in tissue culture (Fig. 1). Explants in-570 nm (Uniskan II plate reader).
Protein concentration in conditioned media was cubated for 2 days (Fig. 1b) were indistinguishable
from the fresh specimens (Fig. 1a). After 4 days (Fig.measured using a colorimetric assay based on the
Bradford dye-binding procedure. Bovine serum al- 1c) some foci of nuclear vacuolation and fragmentation
were observed in the smooth-muscle cells and to abumin was used as the calibration standard.
Matrix metalloproteinase-9 (MMP-9) and in- lesser extent in lymphocytes, but overall tissue in-
tegrity was maintained. After 6 days in vitro, moreflammatory mediators were measured by ELISA tech-
niques, sources given in Table 1. The activation of widespread degeneration of smooth-muscle and in-
flammatory cells was seen (Fig. 1d).MMP-9 was investigated using gelatin zymography.12
Glucose consumption was maximal during the first
4 days of culture, but continued for up to 12 days.
Lactate dehydrogenase release also persisted for over
Cyclo-oxygenase 2 staining 10 days. Hydroxyproline and total soluble protein was
released for the first 48 hours, but fell to low levels
Fresh biopsies of AAA were snap-frozen in liquid thereafter. All these results are summarised in Table
nitrogen and stored at -70 °C. These specimens were 2.
processed for immune staining after preadsorption After 48 hours in culture explants continued to
with biotin using a rabbit polyclonal antibody to cyclo- incorporate [3H]leucine into proteins (Table 2). More
oxygenase 2 (COX2) by Marokh Nohadani, De- specifically, radiolabelled protein was extracted from
partment of Surgery, Hammersmith Hospital. the explants incubated in the presence of [3H]leucine,
confirming active protein synthesis in vitro, and im-
munoprecipitation of labelled MCP-1 (10 kD) dem-
onstrated that production of this cytokine had occurredEffect of indomethacin on AAA explants
during the culture period (data not shown).
The secretion of MMP-9 was highest in the first 2AAA biopsies were established in tissue culture as
days, whereas secretion of MCP-1 increased with timedescribed above. Each biopsy was divided into two;
in culture (Table 2).one incubated as an untreated control, the other in the
presence of indomethacin in a final concentration of
10 lM. The concentration of 10 lM was chosen, as this
is a level typically attained in serum with normal oral
administration of indomethacin. The explants were Cytokine secretion by explants
cultured for 48 hours to allow drugs including
anaesthetic agents to diffuse out of the tissue, then the In addition to the secretion of MCP-1, explants also
secreted high concentrations of PGE2 and IL-6 duringmedium changed. The conditioned media collected
after the second 48 hours of culture were analysed for the first 4 days in culture. The concentrations secreted
between days 2 and 4 are shown in Table 3. Smallermatrix metalloproteinase-9, prostaglandin E2 and the
cytokines interleukin-1b (IL-1b), interleukin-6 (IL-6) concentrations of IL-1b were secreted, but no TNF-a
or IFN-c was detected in the culture medium; this isand MCP-1 as indicated in Table 1.
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Table 2. Explant culture characterisation.
Culture period (days) 2 4 6
Histological appearance Tissue appearances Well preserved appearances, Widespread
n=6 indistinguishable from fresh particularly of lymphocytes. fragmentation of
specimens. No evidence of cell Some foci of nuclear vacuolation lymphocyte and SMC
death of smooth muscle or and fragmentation nuclei
inflammatory cells
Glucose uptake 90.5–13 127–15 110–19
(lmol/g tissue, n=6)
Lactate dehydrogenase release 6.4–0.6 4.6–0.9 4–1
(U/g tissue, n=6)
3H leucine incorporation Incorporation of 3H leucine into
(n=3) protein was approximately 5
times higher (3.5–6.3) in explants
not incubated in the presence of
0.1% sodium azide
Hydroxyproline release 265–24 35–6 16–7
(lg/g tissue, n=19)
Protein release 33–3 4.4–0.9 1.8–0.2
(mg/g tissue, n=9)
MMP-9 release 330–75 165–37 145–95
(ng/g tissue, n=12)
MCP-1 release 245–54 701–23 680–146
(ng/g tissue, n=15)
Numerical data are expressed as mean–standard error of mean.
consistent with other observations that these cytokines Fig. 3). MCP-1 levels were not affected, nor was the
concentration of total MMP-9 (Table 3). Gelatin zym-are frequently tissue-bound and not free to diffuse out
into the culture medium. ography showed no difference in the ratio of pro-
MMP-9 (92 kD) to active MMP-9 (85 kD) in the media
harvested from the indomethacin-treated explants rel-
ative to the untreated controls. Indomethacin had no
effect on the release of hydroxyproline, total proteinCyclo-oxygenase 2 expression
or LDH into the conditioned media.
Cells expressing COX2 were prominent in the AAA
wall, particularly in macrophage-like cells in the ad-
ventitia and in the endothelium of the vasa vasorum
(Fig. 2). Discussion
As an aneurysm enlarges, so the risk of catastrophic
rupture increases. At present, most surgeons agree
that repair is indicated in fit patients with aneurysmsEffect of indomethacin on the secretions of the explants
larger than 5.5 cm in diameter. Early elective surgery
confers no advantage over ultrasonographic sur-PGE2 secretion was almost abolished in the explants
treated with 10 lM indomethacin (Table 3 and Fig. 3). veillance for aneurysms in the range 4–5.5 cm.15 There
is currently no medical treatment to limit expansionIndomethacin also significantly reduced the levels of
IL-1b and IL-6 detected in culture media (Table 3 and of small aneurysms to a dangerous size, nor is there any
Fig. 1. Low, medium and high power views through AAA wall stained with haematoxylin and eosin after different time periods in
explant culture. In all sections the luminal surface is towards the top of the field. (a) Tissue fixed at the time of surgery. There is a marked
inflammatory infiltrate at the interface of tunica media and adventitia and associated with the vasa vasorum. (b) Explants cultured for 2
days are indistinguishable from fresh specimens. (c) After 4 days in culture tissue morphology is well preserved with minimal signs of
cell deterioration. Vacuolation is observed in the nuclei of some lymphocytes and smooth muscle cells. (d) Appearances after 6 days in
culture; widespread degeneration and fragmentation of nuclei is seen.
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Fig. 2. Immunolocalisation of cyclo-oxygenase 2 in aneurysm wall. The endothelium of the capillaries in the adventitia and the
inflammatory cells in the adventitia and media (arrow) stain prominently. Final magnification ·250.
Table 3. Release of PGE2, cytokines and MMP-9 from AAA explants into conditioned medium.
Untreated explants Explants treated with p value
10 lm indomethacin (Wilcoxon signed rank)
PGE2 (ng/ml, n=6) 348 (63–576) 3 (2–6.3) 0.028
IL-1b (pg/ml, n=6) 190 (66–241) 8.5 (0–19.3) 0.04
IL-6 (ng/ml, n=6) 77 (32–267) 38 (22–144) 0.028
MCP-1 (ng/ml, n=5) 33 (11–328) 46 (28–87) Not significant
MMP-9 (ng/ml, n=4) 13 (4–20) 31 (13–40) Not significant
Results are median values with ranges in brackets.
therapy to offer those patients with large aneurysms at and anti-inflammatory agents. There are very few
animal models of AAA to test potential treatments,high risk of rupture, but who are unfit for surgery.
There is an increasing body of evidence that an- and all have inherent problems of species difference
and absence of the risk factors, such as smoking, thateurysmal dilatation of the aorta is not simply a com-
plication of atherosclerosis.16 Although certain risk are present in humans. We have described a convenient
model to assess the effects of potential therapeuticfactors for each condition, especially smoking and
hypertension, are shared, there are important epi- agents on human AAA tissue. The production of
MMPs and mediators of inflammation crucial to an-demiological differences between atherosclerosis and
AAA formation.7 Moreover, atherosclerosis appears eurysm development can easily be quantified, and
differences between treated and untreated specimensprimarily to be a disorder of the tunica intima; in
contrast, aortic aneurysms are characterised by in- detected.
Histological appearances of the explants were wellflammation of the outer medial and adventitial layers
of the vessel wall and extensive degeneration of the maintained in culture with little sign of tissue de-
terioration until after 4 days. Glucose consumptionmedia with loss of elastin and smooth-muscle cells.
The lymphocytes and macrophages in the aneurysm was high for the first 4 days of incubation suggesting
significant metabolic activity in the tissue. The de-wall secrete a range of mediators, including cytokines
and PGE2, which sustain the inflammatory response. monstration of incorporation of radiolabelled leucine
into soluble protein proved that there was active pro-The production of PGE2 by AAA explants is in the
order of 50 times greater than non-aneurysmal aorta.14 tein synthesis during the culture interval, and the
immune precipitation results confirmed that de novoTwo enzymes can catalyse the rate-limiting step in
PGE2 synthesis; COX1 is widespread in normal tissue, synthesis of MCP-1 had occurred. The disadvantages
of this system are those of any ex vivo model. Viabilitywhereas COX2 is confined to areas of inflammation.
COX1 has not been found in AAA tissue,14 but COX2 of tissue and its behaviour may not exactly mimic
the situation in the living organism; the cells mayis expressed widely in macrophages and endothelium
of the vasa vasorum in the aneurysm wall (Fig. 2). differentiate as a response to being placed in culture
or positioned at cut edges. Further, explants in vitroResearch into potential drug therapies for AAA
have focused on three main approaches; treatment of are not subject to haemodynamic strain, nor sur-
rounded by normal physiological conditions. How-hypertension, reduction of matrix proteolytic activity
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are so important in vivo to persist in culture, a feature
lacking in cell monolayer systems.
The effect of indomethacin to inhibit PGE2 secretion
from the explants was anticipated. The more surprising
result was that indomethacin also significantly reduced
production of the cytokines IL-1b and IL-6. Reduced
concentrations of these inflammatory mediators in the
aneurysm wall could have beneficial consequences.
PGE2 has been shown to stimulate MMP-9 activity in
human17 and rat18 lymphocytes. IL-1b has numerous
effects on lymphocytes including prostaglandin and
MMP synthesis.19 IL-1b also induces collagenase gene
expression in human aortic smooth muscle cells.20 IL-
6 stimulates B-cell differentiation and induces release
of acute phase proteins. The result of indomethacin
therapy could therefore be to depress inflammation
and proteolytic activity within the aneurysm wall,
leading to reduced matrix degradation and slower
rates of dilatation.
The principal mechanism of action of non-steroidal
anti-inflammatory drugs, such as indomethacin, is
inhibition of cyclo-oxygenases 1 and 2. A second mech-
anism is mediated via the peroxisome proliferator-
activated receptor-c (PPAR-c). In vitro, indomethacin,
at higher concentrations than those required to inhibit
cyclo-oxygenase, acts as a PPAR-c agonist and inhibits
production of monocyte inflammatory cytokines.21
Indomethacin has been shown to prevent development
of experimental aneurysms in rats,22 and this effect
was associated with decreased production of MMP-9.
Treatment of aortic explants with 10 lM indomethacin
for 2 to 4 days did not alter the amount of total MMP-
9 secreted by the tissue nor was there any difference in
MMP activity detected by zymography. This negative
result may simply reflect the short duration of treat-
ment (2 to 4 days). In a clinical setting therapy would
persist over a much longer time course.
The adverse side-effects of indomethacin are mainly
those of peptic ulceration. PGE2 is produced in the
gastric mucosa by COX1 and modulates gastric acid
secretion and stimulates release of bicarbonate.23 In-
hibition of COX1 by indomethacin therefore leads to
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explants reduced PGE2 production and a decrease in gastric
pH. Specific COX2 inhibitors are becoming available,Fig. 3. Effect of indomethacin on secretion of inflammatory me-
diators by AAA explants. which should have the beneficial effects of COX2
inhibition in the aneurysm wall, while avoiding the
gastroduodenal complications caused by inhibition of
ever, we have demonstrated good viability of the tissue COX1. Evidence is also accumulating that non-
for the first 4 days in culture, sufficient to assess the steroidal anti-inflammatory drugs (NSAIDs) protect
effect of short-term treatment. This model has the against some cancers. Aspirin and other NSAIDs in-
advantage of using human diseased tissue, the precise hibit the development of colorectal cancer in animal
target of the therapy being tested. Moreover, the tissue models and prevent malignant progression in familial
structure is preserved, allowing, to some extent, the polyposis coli.24 Sulindac may protect against colo-
rectal and breast cancer.25 All these agents have anti-paracrine interactions between different cell types that
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